Overview

Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone

Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
0
Participant gender:
All
Summary
Giant cell tumor of bone (GCTb) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of relapsed or refractoriness GCT with denosumab and to assess adverse effect profile and recurrence rate.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hebei Medical University Third Hospital
Treatments:
Denosumab
Criteria
Inclusion Criteria:

- Giant cell tumor of bone patients confirmed by clinical, medical imaging and
Pathology.

Exclusion Criteria:

- (1) less than 14 patients; 2) pregnant patients; 3) A patient who receives other
medications during treatment.